 Archeosomes are liposomes that use total polar lipids or semisynthetic glycolipids derived from archaea to deliver antigens for adjuvant activity. The ad-mixed formulation using a single semisynthetic archaeolipid, SLA, induces similar robust adjuvant activity as an encapsulated formulation, and both result in increased immune cell infiltration, enhanced antigen retention at injection site, and increased antigen uptake by immune cells. In vivo studies demonstrate that both ad-mixed and encapsulated SLA archaeosomes offer strong immunogenicity and efficacy, while the encapsulated formulation is better able to induce antigen-specific CD8 plus T cell activation in vitro. This article was authored by Gerard Ogbionni, E-Major, Basilacatch, and others.